Bacterial Sphingolipids Exacerbate Colitis by Inhibiting ILC3-derived IL-22 Production.

BACKGROUND & AIMS:Gut bacterial sphingolipids, primarily produced by Bacteroidetes, have dual roles as bacterial virulence factors and regulators of the host mucosal immune system, including regulatory T cells and iNKT cells. IBD patients display altered sphingolipids profiles in fecal samples. However, how bacterial sphingolipids modulate mucosal homeostasis and regulate intestinal inflammation remains unclear. METHODS:We utilized DSS-induced colitis in mice mono-colonized with Bacteroides fragilis strains expressing or lacking sphingolipids to assess the influence of bacterial sphingolipids on intestinal inflammation employing transcriptional, protein, and cellular analyses. Colonic explant and organoid were used to study the function of bacterial sphingolipids. Host mucosal immune cells and cytokines were profiled and characterized using flow cytometry, ELISA, and Western Blot, and cytokine function in vivo was investigated by monoclonal antibody injection. RESULTS:B. fragilis sphingolipids exacerbated intestinal inflammation. Mice mono-colonized with B. fragilis lacking sphingolipids exhibited less severe DSS-induced colitis. This amelioration of colitis was associated with increased production of interleukin-22 by ILC3. Mice colonized with B. fragilis lacking sphingolipids following DSS treatment showed enhanced epithelial STAT3 activity, intestinal cell proliferation, and antimicrobial peptide production. Protection against DSS colitis associated with B. fragilis lacking sphingolipids was reversed upon IL-22 blockade. Furthermore, bacterial sphingolipids restricted epithelial IL-18 production following DSS treatment and interfered with IL-22 production by a subset of ILC3 cells expressing both IL-18R and MHC II. CONCLUSION:B. fragilis-derived sphingolipids exacerbate mucosal inflammation by impeding epithelial IL-18 expression and concomitantly suppressing the production of IL-22 by ILC3 cells.